ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formally submit a request for re-examination.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan’s consumption is set for its first decline in over two years? The Bank of Japan preempts with a “precautionary statement”: Weak overall figures due to population shrinkage ≠ deteriorating demand, December rate hike may not be affected
The Bank of Japan stated that, due to the ongoing population decline, it is difficult for overall consumption in Japan to achieve strong growth. However, this also means that overall sluggish consumption does not necessarily indicate weakening household demand.
Swiss Franc remains stronger following SVME PMI data
Alphabet (GOOGL.US) issues euro bonds for the second time this year: Amid AI cash burn concerns, the 19-year bond initial spread guidance reaches 210 basis points.
Alphabet has issued euro-denominated bonds for the second time this year, across seven tranches with maturities ranging from 2 to 19 years. Concerns over AI spending have widened credit spreads, and credit default swap contracts surged by 6.4 basis points in a single day to nearly 91 basis points, reaching a historic high.
Wells Fargo raises Eli Lilly's target price to $1500
Crypto prices
More
